OncoMatch

OncoMatch/Clinical Trials/NCT06057948

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Is NCT06057948 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies OPT-821 (QS-21) for neuroblastoma.

Phase 2RecruitingMemorial Sloan Kettering Cancer CenterNCT06057948Data as of May 2026

Treatment: OPT-821 (QS-21) — The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroblastoma

Biomarker criteria

Allowed: MYCN amplification

Disease stage

Required: Stage HIGH-RISK, IV, NON-LOCALIZED

HR-NB as defined by risk-related treatment guidelines and international criteria, i.e., metastatic/non-localized disease with MYCN amplification (any age), metastatic disease >18 months old, MYCN-amplified localized disease (any age), or disease resistant to standard chemotherapy.

Performance status

CTCAE 3–3

Prior therapy

Must have received: anti-GD2 antibody — immunotherapy

first CR at ≥ 6 months from initiation of immunotherapy using anti-GD2 antibody

Cannot have received: this vaccine

Prior treatment with this vaccine.

Lab requirements

Blood counts

grade 3 toxicities or less using the Common Toxicity Criteria (Version 5.0) developed by the National Cancer Institute of the USA (CTCAE v5.0) related to hematologic function; ANC ≥ 500/mcl; Absolute lymphocyte count ≥ 500/mcl

Kidney function

grade 3 toxicities or less using the Common Toxicity Criteria (Version 5.0) developed by the National Cancer Institute of the USA (CTCAE v5.0) related to renal function

Liver function

grade 3 toxicities or less using the Common Toxicity Criteria (Version 5.0) developed by the National Cancer Institute of the USA (CTCAE v5.0) related to hepatic function

Cardiac function

grade 3 toxicities or less using the Common Toxicity Criteria (Version 5.0) developed by the National Cancer Institute of the USA (CTCAE v5.0) related to cardiac function

Patients with grade 3 toxicities or less using the Common Toxicity Criteria (Version 5.0) developed by the National Cancer Institute of the USA (CTCAE v5.0) related to hematologic, cardiac, neurological, pulmonary, renal, hepatic or gastrointestinal function as determined by blood tests or physical exam. Plus: Absolute neutrophil count (ANC) ≥ 500/mcl; Absolute lymphocyte count ≥ 500/mcl

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Memorial Sloan Kettering at Basking Ridge (Consent only) · Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Consent Only) · Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Consent Only) · Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk-Commack (Consent only) · Commack, New York
  • Memorial Sloan Kettering Westchester (Consent only) · Harrison, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify